- Home
- ISPC vs BCTX Comparison
ISPC vs BCTX Comparison
Compare ISPC & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- BCTX
- Stock Information
- Founded
- ISPC 2009
- BCTX 2014
- Country
- ISPC United States
- BCTX Canada
- Employees
- ISPC N/A
- BCTX N/A
- Industry
- ISPC Precision Instruments
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- BCTX Health Care
- Exchange
- ISPC Nasdaq
- BCTX Nasdaq
- Market Cap
- ISPC 13.9M
- BCTX 14.2M
- IPO Year
- ISPC 2021
- BCTX N/A
- Fundamental
- Price
- ISPC $1.55
- BCTX $9.08
- Analyst Decision
- ISPC
- BCTX Strong Buy
- Analyst Count
- ISPC 0
- BCTX 1
- Target Price
- ISPC N/A
- BCTX $40.00
- AVG Volume (30 Days)
- ISPC 20.5M
- BCTX 85.5K
- Earning Date
- ISPC 11-06-2025
- BCTX 10-28-2025
- Dividend Yield
- ISPC N/A
- BCTX N/A
- EPS Growth
- ISPC N/A
- BCTX N/A
- EPS
- ISPC N/A
- BCTX N/A
- Revenue
- ISPC $5,908,088.00
- BCTX N/A
- Revenue This Year
- ISPC $35.93
- BCTX N/A
- Revenue Next Year
- ISPC N/A
- BCTX N/A
- P/E Ratio
- ISPC N/A
- BCTX N/A
- Revenue Growth
- ISPC N/A
- BCTX N/A
- 52 Week Low
- ISPC $0.64
- BCTX $6.00
- 52 Week High
- ISPC $8.30
- BCTX $214.50
- Technical
- Relative Strength Index (RSI)
- ISPC 56.57
- BCTX 55.50
- Support Level
- ISPC $1.47
- BCTX $7.93
- Resistance Level
- ISPC $2.58
- BCTX $9.33
- Average True Range (ATR)
- ISPC 0.47
- BCTX 0.48
- MACD
- ISPC 0.08
- BCTX 0.35
- Stochastic Oscillator
- ISPC 35.83
- BCTX 87.80
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.